(Q43753029)

English

Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

L Alric

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

M Duffaut

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

J Selves

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

K Sandre

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

M Mularczyck

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

J Izopet

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

H Desmorat

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

C Bureau

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

N Chaouche

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

B Dalbergue

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

J P Vinel

11

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 August 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

272-278

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of hepatitis C: interferon alfa-2a trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of naive patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Early predictors of response to treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Side effects of alpha interferon in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance interferon for chronic hepatitis C: more issues than answers?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900110-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(01)00110-6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43753029&oldid=2103046644"